Anokion SA is spinning out a new start-up, Kanyos Bio Inc., to serve as the vehicle for a development alliance in autoimmune disease with Astellas Pharma Inc., which could be worth up to $760 million in R&D funding, option exercise payments and milestones. Read More
HONG KONG – In a move that sent its stock down more than 3 percent Tuesday, Hong Kong-listed Chinese pharmaceutical company Luye Pharma Group (HK:2186) terminated a billion-dollar acquisition deal. Read More
CHICAGO – No one was surprised to see immune-based therapies taking much of the air time at this year's American Society of Clinical Oncology (ASCO) meeting, since they've dominated the key scientific powwow in cancer for several years, and a fountain of outcomes showed that targeted drugs, in combination regimens as well as single agents, still have plenty going for them. Read More
For antimicrobials, toxicity and the ability to prevent resistance from evolving are widely considered two sides of the same coin. But researchers from the University of Illinois at Urbana-Champaign and The Whitehead Institute have shown that it is possible to separate those two aspects of drugs. Read More
BioWorld is pleased to share Cortellis conference reports from ASCO. The Thomson Reuters Cortellis team covers more than 200 key scientific and biopharma conferences per year, producing nearly 300 such reports. Read More
Lipocine Inc., of Salt Lake City, said the FDA granted orphan status to LPCN 1107, its oral hydroxyprogesterone caproate product candidate, a potential treatment for the prevention of preterm birth. Lipocine previously reported positive phase Ib top-line data with LPCN 1107 in pregnant women. Read More
Cytori Therapeutics Inc., of San Diego, said it entered a four-year, $17.7 million term loan with Oxford Finance LLC. The terms of the loan provide for an interest-only payment period of at least 12 months with the potential to be extended up to 18 months. Read More
TG Therapeutics Inc., of New York, reported clinical results from two ongoing studies of its oral, once-daily, PI3K delta inhibitor, TGR-1202, as a single agent and in combination with TG-1101 (ublituximab), the company's glycoengineered anti-CD20 monoclonal antibody. Read More
Aphios Corp., of Woburn, Mass., said enrollment has completed in a phase I/II trial of APH-0812 for HIV latency. APH-0812 consists of a PKC modulator such as bryostatin-1 and/or an HDAC inhibitor to reactivate latent HIV reservoirs so that HIV-1 can be eliminated from the body by antiviral therapy or immunotherapy and eradicated from the patient's body. Read More
